knowledge -WSS

knowledge

author：comprehensive 2025-10-01 17:21:08 - browse：42

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Donald Trump's relentless attacks on special counsel Jack Smith

explore

WSS

Disclosing genetic information: not as worrisome as once feared

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Donald Trump's relentless attacks on special counsel Jack Smith

Medicare bonuses could stop drug shortages under Senate plan

The inclusion problem at the heart of rehabilitation research

Gene therapy has helped boys walk. Can scientists keep it that way?

knowledge

knowledge

focus

Guidelines to prevent youth baseball injuries need more muscle

Immunocompromised patients offer clues on chronic Covid

Moonlake's readout produced a cash windfall. Risks remain

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Jerome Adams on the need for new antivirals for Covid

Cloning humans is technically possible. It's curious no one has tried

United colonoscopy coverage change 'may cost lives,' doctors say

Colonoscopy at 40? Study finds a possible benefit

BioMarin wins approval for gene therapy to treat hemophilia A

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

entertainment

The science behind Janet Jackson's pregnancy at 49

Future doctors need a strong humanities education

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Immunocompromised patients offer clues on chronic Covid

Inaction leaves children at risk from dangerous chemotherapy drug

Weight bias in eating disorder treatment complicated by new weight loss drugs

hotspot

hotspot

explore

Wikipedia